Must Reads: HUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drug

HUTCHMED (China)'s partner, Takeda, received FDA approval for the sale of FRUZAQLA in the US, leading to a milestone pay

Must Reads HUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drug  HUTCHMED (China)'s partner, Takeda, received FDA approval for the sale of FRUZAQLA in the US, leading to a milestone payment of $35 million for HUTCHM... Continue Reading Grupo Televisa: Wait For A Catalyst Before Buying Grupo Televisa has not been a very good investment over the past few years. The company is a fairly complex entity, including a core cable business, a... Continue Reading UTG And UTF: Enjoy The Recovery, But Don't Keep The Cash Many equity investors are patiently waiting and hoping for a recovery. Utility stocks in particular have been beaten down and UTF and UTG may be good ... Continue Reading KIO: A 12.15%-Yielding Dynamic Income Fund Worthy Of Purchase The KKR Income Opportunities Fund specializes in generating a high level of income for shareholders, with a current yield of 12.15%. The KIO closed-en... Continue Reading SPY: Powell's Friday Speech To Likely 'Kill' The Rally The S&P 500 rallied 10% in November as the financial conditions loosened with the lower interest rates and a weaker US dollar, after the November 1st ... Continue Reading Download the Seeking Alpha App! Like Must Reads? Try our other newsletters as well. This email was sent to you because you signed up to receive Must Reads. If you do not want to receive Must Reads emails, click here to unsubscribe. Sent by Seeking Alpha, 244 5th Ave, Suite 2705, New York, NY 10001